Sugi Predict

Sugi Predict / Compounds / SCHEMBL10044648

SCHEMBL10044648

SCHEMBL10044648

CC(C)(Nc1nc(-c2ccc3ncccc3c2)ncc1F)C(=O)NCC(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 10/20 0.43
▸ KDR P35968 6/20 0.41
▸ JAK3 P52333 3/20 0.40
▸ JAK2 O60674 2/20 0.40
▸ AKR1C3 P42330 1/20 0.39
▸ AKR1C2 P52895 1/20 0.39
▸ PLK4 O00444 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ STK10 O94804 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ PRKCB P05771 1/20 0.39
▸ MET P08581 1/20 0.39
▸ TOP2A P11388 1/20 0.39
▸ PRKCA P17252 1/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ MARK3 P27448 1/20 0.39
▸ TYK2 P29597 1/20 0.39
▸ ABL2 P42684 1/20 0.39
▸ CDK9 P50750 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10044780 0.90 FGFR3 (0.42) FGFR3KDRULK1
SCHEMBL10044685 0.85 JAK3 (0.51) JAK3JAK2AKR1C3AKR1C2PLK4
SCHEMBL10044790 0.83 FGFR3 (0.41) FGFR3KDRULK1
SCHEMBL10044772 0.82 FGFR3 (0.42) FGFR3KDRULK1
SCHEMBL10044667 0.81 PI4KA (0.42) FGFR3KDR
SCHEMBL10044654 0.81 AKR1C3 (0.41) FGFR3KDRJAK3JAK2AKR1C3
SCHEMBL10044732 0.80 ULK1 (0.42) FGFR3KDRULK1
SCHEMBL10044773 0.80 PRMT7 (0.46) FGFR3KDRULK1
SCHEMBL10044644 0.80 PRMT7 (0.46) FGFR3KDRALOX15
SCHEMBL10044665 0.79 PIK3CA (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221336-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 — — US disclosed
US-20140221336-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 — — US disclosed
US-20120157429-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-21 — — US disclosed
US-20120157429-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-21 — — US disclosed
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 — — US disclosed
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 — — US disclosed
WO-2008116139-A2 N-HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157429-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 FGFR3 574/4885KDR 997/4885JAK3 3/4885
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 FGFR3 574/4885KDR 997/4885JAK3 3/4885
US-20140221336-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 FGFR3 574/4885KDR 997/4885JAK3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.